NGL Fine-Chem per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023
₹92.59₹77.90₹34.19₹66.88₹33.18
₹92.59₹77.90₹34.19₹66.88₹33.18
₹532.91₹532.91₹457.16₹425.11₹360.23
₹867.86₹810.87₹596.08₹548.22₹450.11
—₹70.12₹57.98₹33.13₹57.12
−₹75.32−₹75.32−₹153.69−₹13.04₹6.28
—₹1.75₹1.75₹1.75₹1.75
0.60.60.60.60.6
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

NGLFINE₹2,610.60

NGL Fine-Chem Limited

· Pharma & Health
₹ CrorePeersSYNCOMFJAGSNPHARMHESTERBIOAMRUTANJANWINDLASINDOCOSAIPARENTMcap ₹1,613 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS33.1866.8834.1977.9092.59
Diluted EPS33.1866.8834.1977.9092.59
Book Value per Share360.23425.11457.16532.91532.91
Revenue per Share450.11548.22596.08810.87867.86
Cash Flow per Share57.1233.1357.9870.12—
Free Cash Flow per Share6.28-13.04-153.69-75.32-75.32
Dividends per Share1.751.751.751.75—
Shares Outstanding (cr)0.60.60.60.60.6
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.